# Docetaxel in the Treatment of Hormone Refractory Prostate Cancer

> **NCT00280098** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 30 (estimated)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00280098
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-10
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2009-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00280098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00280098, "Docetaxel in the Treatment of Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00280098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*